Authors: Nash, RA Antin, JH Karanes, C Fay, JW Avalos, BR Yeager, AM Przepiorka, D Davies, S Petersen, FB Bartels, P Buell, D Fitzsimmons, W Anasetti, C Storb, R Ratanatharathorn, V

Citation: Ra. Nash et al., Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors, BLOOD, 96(6), 2000, pp. 2062-2068

Authors: Fleming, DR Wolff, SN Fay, JW Brown, RA Lynch, JP Bolwell, BJ Stevens, DA Goodman, SA Greer, JP Stein, RS Pineiro, LA Collins, RH Goldsmith, LJ Herzig, GP Herzig, RH

Citation: Dr. Fleming et al., Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the north American marrow transplant group, LEUK LYMPH, 35(1-2), 1999, pp. 91-98

Authors: Przepiorka, D Devine, SM Fay, JW Uberti, JP Wingard, JR

Citation: D. Przepiorka et al., Practical considerations in the use of tacrolimus for allogeneic marrow transplantation, BONE MAR TR, 24(10), 1999, pp. 1053-1056

Authors: Rowlings, PA Williams, SF Antman, KH Fields, KK Fay, JW Reed, E Pelz, CJ Klein, JP Sobocinski, KA Kennedy, MJ Freytes, CO McCarthy, PL Herzig, RH Stadtmauer, EA Lazarus, HM Pecora, AL Bitran, JD Wolff, SN Gale, RP Armitage, JO Vaughan, WP Spitzer, G Horowitz, MM

Citation: Pa. Rowlings et al., Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer, J AM MED A, 282(14), 1999, pp. 1335-1343